Reference measurement procedure for Δ9-tetrahydrocannabinol in serum

被引：2

作者：

Lott, S. ^{[1
,2
]}

Henrion, A. ^{[1
]}

Malz, F. ^{[3
]}

Kessler, A. ^{[4
]}

Guettler, B. ^{[1
]}

Aderjan, R. ^{[2
]}

机构：

[1] Phys Tech Bundesanstalt, D-38116 Braunschweig, Germany

[2] Univ Heidelberg, Inst Legal Med & Traff Med, D-69115 Heidelberg, Germany

[3] BAM Fed Inst Mat Res & Testing, D-12489 Berlin, Germany

[4] Univ Bonn, Inst Clin Chem & Pharmacol, D-53105 Bonn, Germany

来源：

ANALYTICAL AND BIOANALYTICAL CHEMISTRY | 2008年 / 391卷 / 03期

关键词：

THC; uncertainty of measurement; GUM; threshold value; reference material; primary method; quantitative NMR;

D O I：

10.1007/s00216-008-2065-1

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

An isotope dilution gas chromatography/mass spectrometry (ID-GC/MS) reference measurement procedure for Delta 9-tetrahydrocannabinol (THC) in serum was developed and validated. The method complies with the concept of a ratio primary reference measurement procedure. The uncertainty was determined for two concentrations of THC in serum (1 ng/mL and 2.4 ng/mL). The calculation procedure is based on the Guide to the Expression of Uncertainty in Measurement (GUM). The relative expanded uncertainty was found to be less than 2% for both concentration levels, corresponding to a 95% confidence interval. For the reference method, it was shown that the measurement of THC within the concentration range covered by the current threshold values is very accurate. The method has the potential to provide traceability for the methods used in practical forensics.

引用

页码：1003 / 1010

页数：8

共 50 条

[1] Reference measurement procedure for Δ9-tetrahydrocannabinol in serum
S. Lott
A. Henrion
F. Malz
A. Kessler
B. Güttler
R. Aderjan
[J]. Analytical and Bioanalytical Chemistry, 2008, 391 : 1003 - 1010
[2] Binding of Δ9-tetrahydrocannabinol and Diazepam to Human Serum Albumin
Fanali, Gabriella
Cao, Yu
Ascenzi, Paolo
Trezza, Viviana
Rubino, Tiziana
Parolaro, Daniela
Fasano, Mauro
[J]. IUBMB LIFE, 2011, 63 (06) : 446 - 451
[3] Pharmacokinetic properties of Δ9-tetrahydrocannabinol in serum and oral fluid
Kauert, Gerold F.
Ramaekers, Johannes G.
Schneider, Erhard
Moeller, Manfred R.
Toennes, Stefan W.
[J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2007, 31 (05) : 288 - 293
[4] Separate and combined effects of gabapentin and 9-tetrahydrocannabinol in humans discriminating 9-tetrahydrocannabinol
Lile, Joshua A.
Wesley, Michael J.
Kelly, Thomas H.
Hays, Lon R.
[J]. BEHAVIOURAL PHARMACOLOGY, 2016, 27 (2-3): : 215 - 224
[5] Substitution profile of Δ9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Δ9-tetrahydrocannabinol
Joshua A. Lile
Thomas H. Kelly
David J. Pinsky
Lon R. Hays
[J]. Psychopharmacology, 2009, 203 : 241 - 250
[6] Sublingual administration of Δ9-tetrahydrocannabinol/β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits
Mannila, J
Järvinen, T
Järvinen, K
Tervonen, J
Jarho, P
[J]. LIFE SCIENCES, 2006, 78 (17) : 1911 - 1914
[7] Substitution profile of Δ9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Δ9-tetrahydrocannabinol
Lile, Joshua A.
Kelly, Thomas H.
Pinsky, David J.
Hays, Lon R.
[J]. PSYCHOPHARMACOLOGY, 2009, 203 (02) : 241 - 250
[8] Determination of Δ9-tetrahydrocannabinol in food
Georgi, K
Mavric, E
Speer, K
[J]. DEUTSCHE LEBENSMITTEL-RUNDSCHAU, 2002, 98 (10) : 363 - 366
[9] Excretion of Δ9-tetrahydrocannabinol in sweat
Huestis, Marilyn A.
Scheidweiler, Karl B.
Saito, Takeshi
Fortner, Neil
Abraham, Tsadik
Gustafson, Richard A.
Smith, Michael L.
[J]. FORENSIC SCIENCE INTERNATIONAL, 2008, 174 (2-3) : 173 - 177
[10] Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol
Chan, GCK
Hinds, TR
Impey, S
Storm, DR
[J]. JOURNAL OF NEUROSCIENCE, 1998, 18 (14): : 5322 - 5332

← 1 2 3 4 5 →